Exclusive License Agreement BetweenExclusive License Agreement • February 14th, 2020 • Quadrant Biosciences Inc • Pharmaceutical preparations • New York
This Exclusive License Agreement (hereinafter, "Agreement") is made and is effective as of the date of the last signature below (hereinafter, "Effective Date") by and between The Research Foundation for The State University of New York ("SUNY"), on behalf of Upstate Medical University ("Upstate"), a non-profit educational corporation, organized and existing under the laws of the State of New York, having offices at 750 East Adams St., WH 1109C ,Syracuse, NY 13210 (hereinafter, "Foundation"), The Penn State Research Foundation having a principal place of business at Office of Technology Management, 113 Technology Center, University Park, PA 16802 (hereinafter referred to as "PSRF") (individually "Licensor", collectively "Licensors"), and Quadrant Biosciences Inc., a Delaware corporation, having a primary address at 505 Irving Ave., Suite 3100AB, Syracuse, NY 13210 (hereinafter, "Licensee", and together with Foundation and PSRF, the "Parties", and each individually a "Party").
SUBSCRIPTION AGREEMENTSubscription Agreement • January 2nd, 2020 • Quadrant Biosciences Inc • Pharmaceutical preparations • New York
THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET IS EXPECTED TO DEVELOP FOLLOWING THIS OFFERING.
SUBSCRIPTION AGREEMENTSubscription Agreement • February 14th, 2020 • Quadrant Biosciences Inc • Pharmaceutical preparations • New York
THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET IS EXPECTED TO DEVELOP FOLLOWING THIS OFFERING.
SECURITY AGREEMENTSecurity Agreement • September 28th, 2023 • Quadrant Biosciences Inc • Pharmaceutical preparations • New York
This Security Agreement dated as of June 30, 2023 (this “Agreement”) by and among Quadrant Biosciences Inc., a Delaware corporation (the “Company”), with its primary place of business at 505 Irving Avenue, Suite 3100AB, Syracuse, NY 13210, and Acquiom Agency Services LLC, as collateral agent (in such capacity, together with its permitted successors in such capacity, the “Collateral Agent”) for the holders of notes (the “Holders” and, together with the Collateral Agent, the “Secured Parties”) issued under each Secured Note and Warrant Purchase Agreement (the “Notes”) (each a “Purchase Agreement”), by and among the Company, the Holders and the Collateral Agent:
REGULATION A+ ESCROW AGREEMENTRegulation A+ Escrow Agreement • February 14th, 2020 • Quadrant Biosciences Inc • Pharmaceutical preparations • Delaware
This Escrow Agreement (this "Agreement") is entered into effective February 6, 2020 by and among Quadrant Biosciences Inc, a Delaware corporation (the “Company”), Wefunder Portal, a Delaware limited liability company (referred to herein as both “Wefunder" and “Portal”), and Boston Private Bank and Trust Company, a Massachusetts Trust Company (referred to herein as both the "Bank" and "Escrow Agent").
Exclusive License Agreement Between The Research Foundation for The State University of New York and Quadrant Biosciences Inc. (COVID-19 Saliva Diagnostic)Exclusive License Agreement • April 29th, 2021 • Quadrant Biosciences Inc • Pharmaceutical preparations • New York
This Exclusive License Agreement (hereinafter, “Agreement”) is made and is effective as of the date of the last signature below (hereinafter, “Effective Date”) by and between The Research Foundation for The State University of New York (“SUNY”), on behalf of Upstate Medical University (“Upstate”), a non-profit educational corporation, organized and existing under the laws of the State of New York, having offices at 750 East Adams St., WH 1109C, Syracuse, NY 13210 (hereinafter, “Foundation” or “Licensor”) and Quadrant Biosciences Inc., a Delaware corporation, having a primary address at 505 Irving Ave., Suite 3100AB, Syracuse, NY 13210 (hereinafter, “Licensee”, and together with Foundation, the “Parties”, and each individually a “Party”).
Broker-Dealer AgreementBroker-Dealer Agreement • January 2nd, 2020 • Quadrant Biosciences Inc • Pharmaceutical preparations
This Broker-Dealer Agreement (together with exhibits, this “Agreement”) is entered into by and between Quadrant Biosciences, Inc., a Delaware Corporation (“Client”), and North Capital Private Securities Corporation, a Delaware Corporation (“North Capital”). Client and North Capital agree to be bound by the terms of this Agreement, effective as of December 13, 2019 (the “Effective Date”).
QUADRANT BIOSCIENCES INC. AMENDED AND RESTATED STOCKHOLDERS AGREEMENTStockholders Agreement • January 2nd, 2020 • Quadrant Biosciences Inc • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”) is made and entered into as of this 5th day of March, 2018, by and among QUADRANT BIOSCIENCES INC., a Delaware corporation (the “Company”), and each of the Persons and entities listed on Exhibit A hereto as amended from time to time (the “Stockholders”). Unless otherwise specified in this Agreement, capitalized terms used herein shall have the meanings set forth in Section 1.2 of this Agreement.
LABORATORY SERVICES AGREEMENTLaboratory Services Agreement • February 14th, 2020 • Quadrant Biosciences Inc • Pharmaceutical preparations • Delaware
This Agreement, effective this 13th day of July 2018 (“Effective Date”) is by and between Admera Health LLC (“ADMERA”) and Quadrant Biosciences Inc (“Referring Entity”).
